A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1, Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 68
- Population
- ALL · 18 Years to 80 Years
- Duration
- 2021-10-24 to 2024-10-31
- Intervention
- Fisetin; Placebo
- Comparator
- Placebo group (control group)
- Outcomes measured
- Incidence of Treatment-Emergent Adverse Events — From date of study drug dosing until the end of the study, an average…; Patient Reported Outcomes Questionnaire-Modified Harris Hip Score (mHHS) — Baseline, 8-12 weeks post-op, 6 months post-…; Patient Reported Outcomes Questionnaire- Hip Outcome Score: activities of daily living and sports subscales (HOS-ADL, H…; Patient Reported Outcomes Questionnaire-Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) — Baseli…; Patient Reported Outcomes Questionnaire-Optum Short Form physical and mental component scores (SF-12 PCS and SF-12 MCS)…; Patient Reported Outcomes Questionnaire-Tegner Activity Scale — Baseline, 8-12 weeks post-op, 6 months post-op, and 12…; Patient Reported Outcomes Questionnaire-Numeric Rating Scale for Hip Pain — Baseline, 8-12 weeks post-op, 6 months post…; Patient Reported Outcomes Questionnaire-Patient satisfaction with surgical outcome — Baseline, 8-12 weeks post-op, 6 mo…; Multi and singleplex immunoassays and flow cytometry senescence and SASP marker assessment of peripheral blood — Baseli…; Incidence of revision arthroscopy or other hip surgery required post initial arthroscopy — From day of initial surgery…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Senolytics · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Summary supplies ageing or longevity context.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.